<p id="hl0000067" class="ng-scope">Coronary artery disease (CAD) is prevalent in patients with aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI), but the role of revascularization in this setting is still debated.</p> <p id="hl0000068" class="ng-scope">TAVI candidates have comorbidities and advanced age, frequently denoting high bleeding risk and a higher chance of presenting with complex and calcified coronary lesions<span> </span><button class="j-inline-reference inline-reference" data-refid="bb0005" id="refInSitubb0005">[1]</button><span> </span>; percutaneous coronary intervention (PCI) is, hence, associated with enhanced procedural time, contrast dye, and procedural risks. To increase the complexity in decision making, the clinical presentation of AS may overlap with CAD expression or result from the synergy of the two diseases, although AS seems to stand as the major player, being its sole treatment frequently adequate to alleviate symptoms. Therefore, both the risk and the benefit of coronary revascularization in TAVI are hard to ascertain.</p>